John C. Ashton

2.2k total citations
67 papers, 1.5k citations indexed

About

John C. Ashton is a scholar working on Pharmacology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, John C. Ashton has authored 67 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pharmacology, 25 papers in Molecular Biology and 17 papers in Cellular and Molecular Neuroscience. Recurrent topics in John C. Ashton's work include Cannabis and Cannabinoid Research (31 papers), Neuroscience and Neuropharmacology Research (11 papers) and Neurotransmitter Receptor Influence on Behavior (9 papers). John C. Ashton is often cited by papers focused on Cannabis and Cannabinoid Research (31 papers), Neuroscience and Neuropharmacology Research (11 papers) and Neurotransmitter Receptor Influence on Behavior (9 papers). John C. Ashton collaborates with scholars based in New Zealand, Australia and United Kingdom. John C. Ashton's co-authors include Michelle Glass, Paul F. Smith, Cynthia L. Darlington, Jack Rivers‐Auty, Ian Appleton, Philip W. Brownjohn, Erin D. Milligan, Brad A. Sutherland, Abigail R. Bland and John M. McPartland and has published in prestigious journals such as Nature reviews. Neuroscience, Scientific Reports and Brain Research.

In The Last Decade

John C. Ashton

64 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John C. Ashton New Zealand 18 963 614 308 214 153 67 1.5k
Nils-Olov Hermansson Sweden 7 1.1k 1.2× 543 0.9× 282 0.9× 221 1.0× 155 1.0× 8 1.4k
Erik Ryberg Sweden 12 1.5k 1.5× 725 1.2× 422 1.4× 270 1.3× 212 1.4× 15 1.9k
Lisa Walter Germany 18 1.3k 1.4× 786 1.3× 313 1.0× 379 1.8× 209 1.4× 31 2.2k
Ana I. Castillo Spain 17 616 0.6× 357 0.6× 380 1.2× 152 0.7× 113 0.7× 21 1.3k
Xavier Canat France 11 969 1.0× 919 1.5× 486 1.6× 210 1.0× 125 0.8× 12 1.6k
D. Dussossoy France 12 1.6k 1.6× 857 1.4× 470 1.5× 345 1.6× 200 1.3× 18 2.1k
Shivakumar Subbanna United States 21 500 0.5× 325 0.5× 481 1.6× 112 0.5× 140 0.9× 34 1.2k
Yuki Yamasaki Japan 13 641 0.7× 463 0.8× 250 0.8× 160 0.7× 120 0.8× 50 1.3k
Gaurav Bedse Italy 22 560 0.6× 487 0.8× 248 0.8× 229 1.1× 327 2.1× 26 1.3k
Jim Wager‐Miller United States 17 723 0.8× 461 0.8× 152 0.5× 195 0.9× 86 0.6× 30 994

Countries citing papers authored by John C. Ashton

Since Specialization
Citations

This map shows the geographic impact of John C. Ashton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Ashton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Ashton more than expected).

Fields of papers citing papers by John C. Ashton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Ashton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Ashton. The network helps show where John C. Ashton may publish in the future.

Co-authorship network of co-authors of John C. Ashton

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Ashton. A scholar is included among the top collaborators of John C. Ashton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Ashton. John C. Ashton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bland, Abigail R., et al.. (2020). The effect of metformin in EML4-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent models. Biochemical Pharmacology. 183. 114345–114345. 13 indexed citations
2.
Ashton, John C., et al.. (2019). P2.14-66 Combination ALK and MEK Inhibition in ALK-Positive Lung Cancer. Journal of Thoracic Oncology. 14(10). S857–S857. 1 indexed citations
3.
Bland, Abigail R., Rebekah L. Bower, Mhairi Nimick, et al.. (2019). Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer. European Journal of Pharmacology. 865. 172749–172749. 14 indexed citations
4.
Nimick, Mhairi, et al.. (2017). ALK and IGF-1R as independent targets in crizotinib resistant lung cancer. Scientific Reports. 7(1). 13955–13955. 23 indexed citations
5.
Milne, Michael & John C. Ashton. (2016). Effect of cannabinoids on CGRP release in the isolated rat lumbar spinal cord. Neuroscience Letters. 614. 39–42. 6 indexed citations
6.
Brownjohn, Philip W., et al.. (2014). Effect of styrene maleic acid WIN55,212-2 micelles on neuropathic pain in a rat model. Journal of drug targeting. 23(4). 353–359. 15 indexed citations
7.
Baek, Jean‐Ha, Cynthia L. Darlington, Paul F. Smith, & John C. Ashton. (2013). Antibody testing for brain immunohistochemistry: Brain immunolabeling for the cannabinoid CB2 receptor. Journal of Neuroscience Methods. 216(2). 87–95. 60 indexed citations
8.
Rivers‐Auty, Jack & John C. Ashton. (2013). Age Matching Animal Models to Humans - Theoretical Considerations. Current Drug Discovery Technologies. 10(3). 177–181. 7 indexed citations
9.
Rivers‐Auty, Jack & John C. Ashton. (2013). Vehicles for Lipophilic Drugs: Implications for Experimental Design, Neuroprotection, and Drug Discovery. Current Neurovascular Research. 10(4). 356–360. 8 indexed citations
10.
Ashton, John C.. (2012). Synthetic Cannabinoids as Drugs of Abuse. Current Drug Abuse Reviews. 5(2). 158–168. 29 indexed citations
11.
Breen, Courtney, Philip W. Brownjohn, & John C. Ashton. (2012). The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain. Neuroscience Letters. 508(2). 119–122. 15 indexed citations
12.
Rivers‐Auty, Jack, Simran Maggo, & John C. Ashton. (2011). Neuroprotective effect of hydroxypropyl-β-cyclodextrin in hypoxia-ischemia. Neuroreport. 23(3). 134–138. 15 indexed citations
13.
Smith, Paul F., et al.. (2010). Behavioural Effects of Co-Administration of Δ9-Tetrahydrocannabinol with Fluoxetine in Rats. Pharmacology. 86(2). 125–128. 3 indexed citations
14.
Rivers‐Auty, Jack & John C. Ashton. (2010). The Development of Cannabinoid CBII Receptor Agonists for the Treatment of Central Neuropathies. Central Nervous System Agents in Medicinal Chemistry. 10(1). 47–64. 23 indexed citations
15.
Ashton, John C.. (2008). Pro-Drugs for Indirect Cannabinoids as Therapeutic Agents. Current Drug Delivery. 5(4). 243–247. 9 indexed citations
16.
Ashton, John C., Paul F. Smith, & Cynthia L. Darlington. (2007). The Effect of Δ<sup>9</sup>-Tetrahydrocannabinol on the Extinction of an Adverse Associative Memory. Pharmacology. 81(1). 18–20. 9 indexed citations
17.
Ashton, John C., Ian Appleton, Cynthia L. Darlington, & Paul F. Smith. (2004). Immunohistochemical localization of cannabinoid CB 1 receptor in inhibitory interneurons in the cerebellum. The Cerebellum. 3(4). 222–226. 17 indexed citations
18.
Ashton, John C., Catherine M. Gliddon, Cynthia L. Darlington, & Paul F. Smith. (2003). Effect of Low Body Temperature During Unilateral Labyrinthectomy on Vestibular Compensation in the Guinea Pig. Acta Oto-Laryngologica. 123(4). 448–452.
19.
Barton, John, David Jasper, Robert P. Carroll, et al.. (1998). The Cambridge Companion to Biblical Interpretation. Cambridge University Press eBooks. 25 indexed citations
20.
Ashton, John C.. (1997). The Interpretation of John. T&T Clark eBooks. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nils-Olov Hermansson Breakdown of academic impact, for papers by Erik Ryberg Breakdown of academic impact, for papers by Lisa Walter Breakdown of academic impact, for papers by Ana I. Castillo Breakdown of academic impact, for papers by Xavier Canat Breakdown of academic impact, for papers by D. Dussossoy Breakdown of academic impact, for papers by Shivakumar Subbanna Breakdown of academic impact, for papers by Yuki Yamasaki Breakdown of academic impact, for papers by Gaurav Bedse Breakdown of academic impact, for papers by Jim Wager‐Miller
Rankless by CCL
2026